Table 4.
Univariate and multivariate analyses of factors predictive of mid-term treatment outcome in the training cohort.
| Category | Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| OR (95%CI) | P value | OR (95%CI) | P value | ||
| Clinical predictors | Sex, F/M | 2.356 (1.078–5.148) | 0.032 | 2.760 (1.196–6.368) | 0.017* |
| Age, <60/≥60 | 0.807 (0.374–1.740) | 0.584 | |||
| LDH level, normal/elevated | 2.130 (0.823–5.513) | 0.119 | |||
| B symptoms, no/yes | 3.647 (1.703–7.813) | 0.001 | 4.065 (1.837–8.955) | 0.001* | |
| ECOG PS, 0–1/≥2 | 0.667 (0.193–2.299) | 0.521 | |||
| IPI, 0–2/≥3 | 1.148 (0.441–2.985) | 0.778 | |||
| NCCN-IPI, 4–5/6–8 | 1.467 (0.524–4.109) | 0.466 | |||
| Ann Abor stage, I-II/III-IV | 2.368 (0.471–11.909) | 0.296 | |||
| Extranodal involvement, 0–1/≥2 | 0.515 (0.174–1.526) | 0.231 | |||
| Bone marrow involvement, no/yes | 0.787 (0.305–2.029) | 0.620 | |||
| Bulky disease, no/yes | 0.853 (0.268–2.717) | 0.788 | |||
| Pathological type, GCB/non-GCB | 0.982 (0.426–2.265) | 0.967 | |||
| PET predictors | SUVmax | 2.672 (1261–5.659) | 0.010 | 2.619 (1.107–6.194) | 0.028* |
| MTV | 3.108 (1.224–7.893) | 0.017 | 2.331 (0.432–12.586) | 0.325 | |
| TLG | 2.503 (1.109–5.649) | 0.027 | 0.698 (0.155–3.156) | 0.641 | |
| Radiomics predictors | RadScore | 7.931 (3.257–19.314) | 0.001 | 7.167 (2.815–18.248) | 0.001* |
CI, confidence interval; OR, odds ratio; F, female; M, male; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; NCCN-IPI, National Comprehensive Cancer Network International Prognostic Index; GCB, germinal centre B cell; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; RadScore, Radiomics Score.
*P < 0.05.